Medical News

RSS

Immersion signs non-exclusive, worldwide license agreement with Simbionix USA

Immersion Corporation, the leading developer and licensor of haptics technology, and Simbionix USA Corporation, the world's leading provider of simulation and training products for medical professionals and the healthcare industry, today announced that the companies have entered into a new license agreement and have successfully settled litigation that was pending in the United States District Court for the Northern District of Ohio.

7 Jun 2010

GSK submits BENLYSTA MAA for systemic lupus erythematosus

Human Genome Sciences, Inc. today announced that GlaxoSmithKline (GSK) has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for approval to market BENLYSTA® (belimumab) for the treatment of systemic lupus erythematosus (SLE).

7 Jun 2010

Pharmacoeconomic methods influence only 13% of hospital formulary system decisions: Survey

Pharmacoeconomic methods rank low as a decision influencer on formulary changes, according to a new survey released today by the Society of Hospital Medicine and the American Society of Health-System Pharmacists. Respondents reported that only 13 percent of formulary system decisions made by Pharmacy and Therapeutics committees in hospitals is influenced by pharmacoeconomic methods.

7 Jun 2010

Cytheris completes €12 million Series D financing

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has completed a €12 million ($15 million) Series D financing.

7 Jun 2010

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

Millennium: The Takeda Oncology Company today reported on data from oral presentations of VELCADE® (bortezomib) for Injection based therapy in multiple myeloma presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). These data highlight VELCADE based therapy in both transplant and non-transplant eligible previously untreated multiple myeloma patients, as well as VELCADE used as induction and/or maintenance therapy.

7 Jun 2010

ASHP honors First DataBank pharmacist with the title of Fellow for excellence in pharmacy practice

First DataBank, a leading provider of drug databases that help drive patient safety, today announced that the American Association of Health-System Pharmacists will honor First DataBank pharmacist Joan Kapusnik-Uner, Pharm.D, with the title of "Fellow" in recognition of the excellence she has achieved in pharmacy practice. The 2010 Fellows will be honored on Tuesday, June 8, 2010, during the ASHP Summer Meeting in Tampa, FL.

7 Jun 2010

Sanofi-aventis reports new 1-year data from teriflunomide Phase II study for relapsing multiple sclerosis

Sanofi-aventis reported today new one-year data from a Phase II study with teriflunomide, a novel oral disease modifier being investigated for the treatment of relapsing multiple sclerosis (RMS). Study results demonstrated an improvement in outcomes, with a consistent safety profile with the data from a previous Phase II monotherapy study, in patients treated with interferon beta (IFN-[BETA]) - a standard therapy in RMS - and receiving teriflunomide 7mg or 14mg, compared with patients treated with IFN-[BETA] and receiving oral placebo.

7 Jun 2010

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer

Amgen today announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer. The results are being presented for the first time in an oral presentation at the 2010 American Society of Clinical Oncology Annual Meeting.

7 Jun 2010

Genta reports combined data from Genasense Phase 3 trials for advanced melanoma

Genta Incorporated announced today the presentation of combined data on early endpoints from the Company's randomized Phase 3 trials of Genasense® (oblimersen sodium) Injection plus chemotherapy in patients with advanced melanoma. The presentation included a "pooled analysis" that assessed combined efficacy results for the endpoints of overall response and progression-free survival from both studies. The data were presented today at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.

7 Jun 2010

Strained relationship with parents following stroke increases depression in daughters: Study

Adult daughters caring for a parent recovering from stroke are more prone to depression than sons, Marina Bastawrous today told the Canadian Stroke Congress, co-hosted by the Canadian Stroke Network, the Heart and Stroke Foundation, and the Canadian Stroke Consortium.

7 Jun 2010

TransMedia to publicize Protectus Automatic, Self-Sheathing Safety Syringe

Protectus Medical Devices, Inc. has retained TransMedia Group to publicize the first automatic, self-sheathing syringe designed to eliminate accidental needle stick injuries that claim the lives of medical professionals and force the industry to spend billions of dollars testing and treating victims for blood borne diseases.

7 Jun 2010

PharmaTelevision offers biopharma companies opportunity to reach key decision makers in financial sector

PharmaTelevision today announced that it is offering pharma and biotech companies the opportunity to reach key decision makers in the financial sector. To celebrate their new relationship with Reuters Insider, PharmaTelevision is offering companies an opportunity to film, host and promote their financial or corporate messages between 21-25 June 2010.

7 Jun 2010

Bevacizumab extends progression-free survival in women with advanced ovarian cancer

Newly reported results from a major clinical trial show that adding bevacizumab (Avastin) to standard frontline chemotherapy for women with advanced ovarian cancer and then continuing a maintenance dose of the drug afterwards significantly extends progression-free survival. Women receiving the new treatment regimen saw no worsening of their disease for 14.1 months, compared to 10.3 months for women receiving standard therapy.

7 Jun 2010

Chemotherapy delivered directly into liver blood vessels increases progression-free survival in melanoma patients

Patients undergoing treatment for melanoma that has spread to the liver may respond well to chemotherapy delivered directly into the liver's blood vessels, according to a study sponsored by the National Cancer Institute and Delcath Systems Inc., and led by James F. Pingpank, M.D., associate professor of surgery, University of Pittsburgh School of Medicine, and surgical oncologist with UPMC Cancer Centers. The results will be disclosed in an oral presentation on June 5 in Chicago at the 46th annual meeting of the American Society of Clinical Oncology (ASCO).

7 Jun 2010

Allos Therapeutics reports data from PROPEL trial of FOLOTYN in patients with PTCL

Allos Therapeutics, Inc. today reported new analyses of data from the Company's pivotal PROPEL trial of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma.

7 Jun 2010

The Iacocca Family Foundation and Kineta partner to develop Type 1 diabetes mellitus drug

Kineta, Inc. joined with The Iacocca Family Foundation today to announce a new investment partnership to speed development of Kineta's preclinical autoimmune drug candidate - ShK-186 - and its multiple applications to treat Type 1 diabetes mellitus.

7 Jun 2010

Economic, clinical benefits of HyperQ stress test presented at International Congress on Electrocardiology

BSP Biological Signal Processing Ltd., develops and markets innovative systems for non-invasive diagnosis and monitoring of Ischemic Heart Disease based on its proprietary HyperQ technology. BSP recently presented the results of a study on the economic and clinical benefits of the HyperQ stress test in the diagnosis and management of coronary heart disease at the International Congress on Electrocardiology on June 4th, 2010.

7 Jun 2010

Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients

Results of a Phase III study presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's eribulin mesylate significantly improved median overall survival (OS) compared with Treatment of Physician's Choice (TPC) in heavily pre-treated metastatic breast cancer patients.

7 Jun 2010

Bisphosphonates may cause poorer survival rate in women with early stage breast cancer: Study

Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit presented preliminary data that shows nitrogen-containing bisphosphonates, therapeutic agents used to promote bone health and inhibit resorption, may cause a slightly poorer survival rate in post-menopausal women with early stage breast cancer who take them for their anti-osteoporosis properties.

7 Jun 2010

Exelixis reports updated interim data from trials of XL765 small molecule inhibitor of PI3K and mTOR

Exelixis, Inc. today reported updated interim data from three ongoing trials of XL765 (SAR245409), an orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mTOR. Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival, and resistance to chemotherapy and radiotherapy.

7 Jun 2010

Medical News

Immersion signs non-exclusive, worldwide license agreement with Simbionix USA

GSK submits BENLYSTA MAA for systemic lupus erythematosus

Pharmacoeconomic methods influence only 13% of hospital formulary system decisions: Survey

Cytheris completes €12 million Series D financing

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

ASHP honors First DataBank pharmacist with the title of Fellow for excellence in pharmacy practice

Sanofi-aventis reports new 1-year data from teriflunomide Phase II study for relapsing multiple sclerosis

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer

Genta reports combined data from Genasense Phase 3 trials for advanced melanoma

Strained relationship with parents following stroke increases depression in daughters: Study

TransMedia to publicize Protectus Automatic, Self-Sheathing Safety Syringe

PharmaTelevision offers biopharma companies opportunity to reach key decision makers in financial sector

Bevacizumab extends progression-free survival in women with advanced ovarian cancer

Chemotherapy delivered directly into liver blood vessels increases progression-free survival in melanoma patients

Allos Therapeutics reports data from PROPEL trial of FOLOTYN in patients with PTCL

The Iacocca Family Foundation and Kineta partner to develop Type 1 diabetes mellitus drug

Economic, clinical benefits of HyperQ stress test presented at International Congress on Electrocardiology

Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients

Bisphosphonates may cause poorer survival rate in women with early stage breast cancer: Study

Exelixis reports updated interim data from trials of XL765 small molecule inhibitor of PI3K and mTOR

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Latest News